Yahoo · Sep 24, 2026
What J&J’s Spravato patent win could mean for psychedelic drugs
As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.
OTC · SDZNY
Sandoz Group AG
Healthcare · Drug Manufacturers - Specialty & Generic
$84.28
Up+$0.28 (+0.33%)
Updated Oct 11, 2026, 8:12 PM
SID Score
5.0/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 32.05B
- P/E ratio
- 140.61
- Dividend yield
- 0.86%
- 52-week range
- — – —
- Volume
- 11.6K
- Avg. volume
- 23.64K
Price performance · SDZNY
SDZNY price history
1M range · 0 trading sessions · Daily adjusted prices
SDZNY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest SDZNY news
The latest Smart Investors Daily articles mentioning SDZNY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SDZNY research
Overview
Company profile and research snapshot.
Company profile
SANDOZ GROUP AG S/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $66.64
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Sep 23, 2026 | JEFFERIES | Buy | — |
| Sep 21, 2026 | BERENBERG | Hold | — |
| Sep 17, 2026 | BAADER EUROPE / ALPHAVALUE | Buy | — |
| Aug 31, 2026 | BNP PARIBAS | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 24, 2026
Podcast: How Sandoz plans to harness its “golden decade”
Sandoz’s chief commercial officer discusses the company’s ambitions plans to have a biosimilar-driven growth engine by 2040.
Yahoo · Sep 21, 2026
Why Everyone Is Watching Sandoz Group (SWX:SDZ) Today
Sandoz Group (SWX:SDZ) has moved back into focus after partnering with mAbxience on a proposed emicizumab biosimilar for hemophilia A, adding another rare disease project to its global generics and biosimilars portfolio. Recent announcements around GLP-1 products, fresh bond issuance in Europe and new biosimilar capacity in Slovenia have arrived during a mixed stretch for Sandoz Group, with a 30-day share price return down 7.07% but a 1-year total shareholder return of 44.28% that points to...
Yahoo · Sep 21, 2026
Sandoz and mAbxience agree on emicizumab biosimilar partnership
mAbxience will lead the development and production of the biosimilar candidate at its manufacturing facilities in Argentina and Spain.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
